14 analysts have expressed a variety of opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $6.79, a high estimate of $8.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 2.57% from the previous average price target of $6.62.

Investigating Analyst Ratings: An Elaborate Study

In examining recent analyst actions, we gain insights into how financial experts perceive Taysha Gene Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Taysha Gene Therapies's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Taysha Gene Therapies analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind Taysha Gene Therapies

Unraveling the Financial Story of Taysha Gene Therapies

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Decline in Revenue: Over the 3 months period, Taysha Gene Therapies faced challenges, resulting in a decline of approximately -27.52% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Taysha Gene Therapies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -705.39% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -37.37%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Taysha Gene Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.77%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Taysha Gene Therapies's debt-to-equity ratio surpasses industry norms, standing at 1.13. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: Simplified

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.

This article was generated by Benzinga's automated content engine and reviewed by an editor.